M Pharmaceutical Acquires Rights to FDA-Cleared Infertility Treatment

M Pharmaceutical Inc. closes acquisition of FDA cleared innovative infertility treatment — a natural conception lubricant.

M Pharmaceutical Inc. has closed its previously announced agreement to acquire from ToConceive LLC., an arms-length private pharmaceutical company, the rights to an FDA-approved women’s health product used as a natural conception lubricant as an infertility treatment. The company issued 20 million shares and will pay a 5 percent royalty on sales.

“In 2010 the Nobel Prize in Medicine for In Vitro Fertilization emphasized the importance of Sperm Capacitation — the process when a women’s natural conception lubrication, transudate, dissolves the immobilizing cholesterol from the sperm and creates an enzyme to allow the sperm to fertilize the ovum — for successful conception. This essential capacitation step is inadequate or missing in many couples due to the women’s limited production of transudate,” Gary Thompson, CEO of M Pharma USA, said.

“This acquisition is our entry into the women’s health market to complement our existing obesity portfolio and has a 510K FDA clearance, is protected by four USPTO patents, and is clinically proven to increase a women’s production of transudate. This increase in transudate results in significantly higher success rates for couples trying to conceive without the added expense, or stress, associated with assisted reproduction treatments,” Thompson added.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing technologies for obesity and weight management. In addition to its recent acquisition of C-103, a reformulation of orlistat from Chelatexx, LLC, the company will focus on the development of its Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity, for which it has exclusive rights.